Cetuximab (Erbitux®) Combo More Effective Than Cetuximab Alone in Colorectal Cancer A randomized phase II trial showed that the combination of cetuximab (Erbitux®) and irinotecan (CPT-11) shrank tumors in more patients and delayed tumor progression longer than cetuximab alone in patients with metastatic colorectal cancer that had progressed after treatment with standard irinotecan-based chemotherapy http://www.cancer.gov/clinicaltrials/results/cetuximab-combo-effective0603
New Cancer Drugs Open Up New Era in Treatment The results showed that more than two times the number of patients taking Erbitux in combination with chemotherapy saw a 50 % reduction in tumor size, compared with the number of patients taking Erbitux alone. In addition, the average time it took for the disease to progress for patients taking the combination therapy was about 4 months compared with 1.5 months for those taking Erbitux alone. http://www.canhope.com.sg/news_events/new_cancer.html